Related Experiment Video
Updated: Jul 7, 2026
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Patency of the Cavernous Sinus After Medial Wall Resection: An Observational Study
Axel E Renteria1, Maxime Fieux1,2,3, Bruna Castro1
1Department of Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, United States.
Insights
Cavernous sinus medial wall resection during tumor removal often preserves sinus patency, with most patients maintaining flow post-surgery. Preoperative sinus non-patency is the primary predictor of persistent blockage after cavernous sinus tumor treatment.
Area of Science:
- Neurosurgery
- Endoscopic Skull Base Surgery
- Vascular Neurosurgery
Background:
- Resection of the cavernous sinus medial wall (CSMW) is necessary for treating tumors invading the cavernous sinus (CS).
- Intraoperative bleeding during CS surgery necessitates hemostatic agents, but the impact on CS patency is unknown.
- This study addresses the gap in literature regarding CS patency after CSMW resection.
Purpose of the Study:
- To investigate the fate of cavernous sinus (CS) patency after endoscopic endonasal approach (EEA) surgery involving CSMW resection for CS-invading tumors.
- To identify predictors of postoperative CS non-patency.
Main Methods:
- Observational study of 186 patients undergoing EEA with CSMW or transcavernous resection (2018-2025).
- Pre- and postoperative MRI analysis of CS patency at 0-3, 3-12, and >12 months.
- Demographic data analysis to identify predictors of CS non-patency.
Main Results:
- Postoperative CS patency was achieved in 87.1% of patients at a mean of 3.72 months.
- Preoperative CS non-patency, incomplete tumor resection, meningioma, and prior radiation increased non-patency risk.
- Multivariate analysis identified preoperative CS non-patency as the sole independent predictor (OR=9.8, p<0.001).
Conclusions:
- This is the first study to demonstrate that CS patency is generally preserved after EEA requiring CSMW resection.
- Preoperative CS non-patency is a strong predictor of postoperative CS non-patency.
- Further research is needed to correlate CS non-patency with clinical outcomes.
Introduction:
The cavernous sinus medial wall (CSMW) is a critical structure that can be resected in cavernous sinus (CS)-invading tumors. Intraoperative venous bleeding is inevitable upon entering the CS and necessitates hemostatic agents use to cease its flow. There is no literature on the fate of CS patency after such hemostasis. This study aims to address that gap.
Methods:
An observational study was conducted between 2018 and 2025, including patients undergoing endoscopic endonasal approach (EEA) with CSMW or transcavernous resection for CS-invading tumors. Pre- and postoperative magnetic resonance imaging (MRI) images were collected and analyzed for CS patency. Postoperative imaging was grouped into three intervals: 0 to 3, 3 to 12, and >12 months. Demographic data were analyzed to identify predictors of CS non-patency.
Results:
Of the 186 patients included, postoperative CS patency was achieved in 87.1% after 3.72 months. Univariate analysis demonstrated that preoperative CS non-patency ( p < 0.001), incomplete gross tumor resection ( p = 0.015), meningioma diagnosis ( p < 0.001), and previous head and neck radiation increased the postoperative CS non-patency risk. Multivariate analysis identified preoperative CS non-patency as the only independent factor for postoperative CS non-patency (odds ratio = 9.8, p < 0.001). Persistent non-patency at 3 and 12 months increased long-term postoperative CS non-patency risk by 5.86 and 14.7 times, respectively.
Conclusion:
This is the first study to report that postoperative CS patency is preserved in most cases after EEA requiring CSMW. A strong predictor of postoperative CS non-patency was identified as preoperative CS non-patency. Further studies are warranted to assess if CS non-patency has significant clinical correlations.